OncoDNA has been nominated for 2020 Deloitte’s Technology Fast 50 competition for technology companies headquartered in Belgium and founded in Belgium. The Fast 50 award will be given to the country’s fastest-growing technology company, based on its percentage of growth in turnover during the last four years.The winning companies will be announced at the Awards Ceremony on 26 November 2020.
OncoDNA is a healthcare technology company that makes precision medicine in oncology a reality.
“As winner of the 2015 and 2018 editions, we are pleasantly surprised and absolutely honoured to be nominated for the Deloitte’s Technology Fast 50 this year again. We are deeply grateful to Deloitte for this symbolic recognition of our strategy and continuous success. It shows that we are on the right track and that we keep on growing stronger and bigger”, says Jean-Pol Detiffe, OncoDNA Founder.
ABOUT THE DELOITTE’S 2020 TECHNOLOGY FAST 50
The Technology Fast 50 competition is an annual selection of the 50 fastest growing and innovative technology companies headquartered and founded in Belgium. Public or private companies who develop a technology related product or service and who have experienced substantial revenue growth over the last four years can enter the competition for their chance to be nominated as one of the 50 fastest-growing technology companies in Belgium.
Companies that have been active in the technology sector for less than four years can participate in the special Rising Star category of the competition. These companies are judged by an independent jury on their turnover potential and scalability.
Participating in the Technology Fast 50 competition can help companies to develop their business by increasing their visibility and giving them access to the Fast 50’s unique network of highly successful executives.
ABOUT ONCODNA
OncoDNA is a private, oncology-focused healthcare technology company that combines advanced, comprehensive testing of all clinically relevant cancer biomarkers (DNA, RNA and protein profiles) from both solid and liquid biopsies with a proprietary cancer treatment knowledge database called OncoKDO™ which continuously ‘learns’ from cutting-edge, validated, scientific and medical advances.
This one-stop-shop analysis and interpretation service gives oncologists actionable results to enable the selection of treatments tailored to the individual patient’s cancer profile. For laboratories worldwide with NGS facilities that would like to reach the same level of expertise, OncoDNA provides them with state-of-the-art interpretation software to improve their oncology-oriented analyses routine work. The software OncoKDM is a web-based tool that processes oncology raw NGS data to turn data into clinical insight such as treatment options or clinical trials.
OncoDNA also works in collaboration with the biopharma industry to develop and deliver the treatments of tomorrow by assisting with design, enrolment and assessment of clinical trials as well as increasing access to approved precision medicines.
The company is based in Gosselies, Belgium, employs approx. 50 employees in four countries, works with an international network of 35 distributors covering approx. 50 countries and is collaborating with a sub-contracted laboratory of 300 collaborators.
